Solutions for increasing the stability and shelf life of an organ and tissue preservation solution
Organ and tissue preservation solutions having improved stability are disclosed. The solutions are comprised of two separate solutions. The first solution, Solution A, is comprised of a balanced salt solution that is stable in solution at a pH of 7.0 or above. A second solution, Solution B, is comprised of an aqueous solution containing L-glutathione and/or cysteinylglycine, a sugar such as D-glucose, L-Arginine, a reducing agent such as ascorbic acid and water at a pH of below 7.0, preferably from about 3.0 to 5.0. The two Solutions are then mixed together at the point of use and the pH adjusted to about 7.3 resulting in the organ and tissue preservation solution having improved stability. Preferably, solution A has a pH of about 7.6 and solution B has a pH of about 5.0. The present invention is also comprised of kits 20 that contain the two Solutions in two separate containers 22, 24 . In an alternate embodiment, the sugar can be in Solution A.
1. An organ and tissue preservation kit, comprising:
a first precursor aqueous solution contained in a first container, and
a second precursor solution contained in a second container;
wherein the first precursor aqueous solution comprises a balanced salt solution, has a pH of about 7.4 to 8.0, and does not include reduced glutathione, ascorbic acid, or LArginine;
wherein the second precursor solution comprises water, reduced glutathione, ascorbic acid, a sugar, L-Arginine and said second precursor solution has a pH of about 3.0 to 4.0; and
wherein a mixture of the first precursor aqueous solution and the second precursor solution provides an organ and tissue preservation solution having a pH of about 7.3.
2. The kit of claim 1 , wherein the first and second containers are first and second chambers within a single container and the first and second chambers are partitioned off from each other by a partition,
wherein, upon removal of the partition, the first precursor aqueous solution mixes with the second precursor solution to form the organ and tissue preservation solution.
3. The kit of claim 1 , wherein the pH of the first precursor aqueous solution is about 7.8 and the pH of the second precursor solution is about 3.0.
4. The kit of claim 1 , wherein the pH of the first precursor aqueous solution is about 7.6 and the pH of the second precursor solution is about 4.0.
5. The kit of claim 1 , wherein the first precursor aqueous solution and/or second precursor solution are formulated in a gel, ointment, lotion or hydrogel.
6. The kit of claim 1 , wherein the sugar is glucose.
7. The kit of claim 6 , wherein the organ and tissue preservation solution comprises the ascorbic acid in a concentration of about 25-1000 μM, the glutathione in a concentration of about 50-2000 μM, the L-arginine in a concentration of about 250-2000 μM, and the glucose in a concentration of about 50-120 mM.
8. The kit of claim 7 , wherein the balanced salt solution comprises:
calcium chloride dihydrate in a concentration of about 0.14 g/L;
potassium chloride in a concentration of about 0.4 g/L;
potassium phosphate monobasic in a concentration of about 0.06 g/L;
magnesium chloride hexahydrate in a concentration of about 0.1 g/L;
magnesium sulfate heptahydrate in a concentration of about 0.1 g/L
sodium chloride in a concentration of about 8 g/L;
sodium bicarbonate in a concentration of about 0.36 g/L; and
sodium phosphate dibasic heptahydrate in a concentration of about 0.03 g/L.
9. The kit of claim 1 , wherein the first precursor aqueous solution and the second precursor solution are provided in a volumetric ratio of 19:1, respectively.